2,970 reports of this reaction
4.5% of all GLIMEPIRIDE reports
#1 most reported adverse reaction
BLOOD GLUCOSE INCREASED is the #1 most commonly reported adverse reaction for GLIMEPIRIDE, manufactured by Lifsa Drugs LLC. There are 2,970 FDA adverse event reports linking GLIMEPIRIDE to BLOOD GLUCOSE INCREASED. This represents approximately 4.5% of all 66,685 adverse event reports for this drug.
Patients taking GLIMEPIRIDE who experience blood glucose increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE INCREASED is moderately reported among GLIMEPIRIDE users, representing a notable but not dominant share of adverse events.
In addition to blood glucose increased, the following adverse reactions have been reported for GLIMEPIRIDE:
The following drugs have also been linked to blood glucose increased in FDA adverse event reports:
BLOOD GLUCOSE INCREASED has been reported as an adverse event in 2,970 FDA reports for GLIMEPIRIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE INCREASED accounts for approximately 4.5% of all adverse event reports for GLIMEPIRIDE, making it one of the most commonly reported side effect.
If you experience blood glucose increased while taking GLIMEPIRIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.